Last update: June 4, 2016
Safe. Compatible.
Not risky for breastfeeding or infant.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
ジルチアゼム塩酸塩 is Diltiazem Hydrochloride in Japanese.
Is written in other languages:Main tradenames from several countries containing ジルチアゼム塩酸塩 in its composition:
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is excreted in breast milk in a clinically non-significant amount (Okada 85)
Two 6 months-old breastfed twins whose mother was treated with diltiazem did not get into health problems (Lubbe 87)
Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Diltiazem does not have any influence on prolactin production.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.
American Academy of Pediatrics: medication usually compatible with breastfeeding.